RE:No Love For DOCIndeed this is frustrating. DOC is a "show us the money" story on 2 fronts:
1 - continue to win new business at slightly higher than organic rate (not too aggressive pace as it will increase costs of acquisition, onboarding and integrations)
2 - breakeven and then profitability
Till these 2 materialize, I do not expect to see a significant uplift in share price. One exception could be if DOC onboards a major well established brand as a client in a mega million deal. But that is unlikely. Best bet for DOC is to target SMB (Small Medium Business) clients where the health technology giants do not play.
I maintain that DOC is going to be bought out when its profitable as industry will undoubtedly move towards consolidation.